ライフサイエンスコーパス: tramadol

1 -inflammatory drugs and weak opioids such as tramadol).

2 /- 0.01 h for iopromide to 3.3 +/- 0.3 h for tramadol.

3 2010 usually for hydrocodone, oxycodone, or tramadol.

4 was lower for tricyclic antidepressants and tramadol.

5 done, hydromorphone, fentanyl, morphine, and tramadol.

6 metabolites, such as the ones of cocaine and tramadol.

7 ase in naproxen dosage after the addition of tramadol.

8 .63 to -0.30 percentage points [pp]/quarter; tramadol: -0.27; 95% CI, -0.36 to -0.17 pp/quarter; bupr

9 8.2%, cannabis 3.3%, buprenorphine 2.2%, and tramadol 1.1%.

10 common opioid substance (49.7%), followed by tramadol (18.4%), and methamphetamine was the most commo

11 fen (2.3 (1.5 to 3.4)), and paracetamol plus tramadol (2.1 (1.3 to 3.4)) compared with placebo.

12 to 4.5)), paracetamol plus sustained release tramadol (2.4 (1.5 to 3.8)), baclofen (2.3 (1.5 to 3.4))

13 ng to naproxen 1,000 mg/day, the addition of tramadol 200 mg/day allows a significant reduction in th

14 domized in a double-blind manner to continue tramadol 200 mg/day or to begin placebo in addition to n

15 Tramadol 200 mg/day was added during the third week.

16 posed to codeine, 4540 to oxycodone, 1244 to tramadol, 260 to methadone (dispensed for pain), 90 to h

17 (237 +/- 20 min), APAP/C (311 +/- 26 min) or tramadol (311 +/- 10 min) (p = 0.12).

18 Oxycodone 5 mg, codeine 60 mg, and tramadol 37.5 mg plus acetaminophen 325 mg were no bette

19 bo (69 +/- 7 min), APAP/C (74 +/- 15 min) or tramadol (686 +/- 8 min) (p = 0.86) were seen.

20 nsation during the study period (326 921 for tramadol, 762 492 for codeine, 3651 for both drugs conco

21 eeded to treat: 4), meperidine (16; 2.2, 2), tramadol (8; 2.2, 2), nefopam (7; 2.1, 2), and ketamine

22 pressive properties (oxycodone, oxymorphone, tramadol) accounting for demographics, opioid dose, como

23 ved placebo (n = 157), patients treated with tramadol/acetaminophen (n = 156) showed greater improvem

24 Patients received either tramadol/acetaminophen or placebo 4 times/day as needed

25 her comparative and quantitative analysis of tramadol adverse reactions.

26 oxycodone (aHR, 1.70; 95% CI, 1.04-2.77) or tramadol (aHR, 2.80; 95% CI, 1.34-5.84) compared with co

27 The obtained degradation pathway of tramadol allowed the correlation of changes in NDMA FP d

28 Tramadol and APAP/C had no effect on gastric emptying or

29 The GC for tramadol and APAP/C were all significantly lower at 72 h

30 When treated with the FDA-approved drugs tramadol and escitalopram oxalate, they release or uptak

31 from the opioid cohort behaves similarly to tramadol and has an association with hypoglycemia.

32 hloramine decreased the degradation rates of tramadol and its byproducts and yielded several monochlo

33 Tramadol and venlafaxine showed constant concentrations

34 r tricyclic antidepressants, strong opioids, tramadol, and botulinum toxin A, and undetermined for li

35 escribing rates of opioids (typical opioids, tramadol, and buprenorphine) and gabapentinoids (gabapen

36 tly studied include remifentanil, methadone, tramadol, and codeine.

37 tions were significant only for hydrocodone, tramadol, and codeine.

38 Systemic baclofen, gabapentin, tramadol, and morphine dose-dependently attenuated tacti

39 il, gabapentin, methamphetamine, sertraline, tramadol, and venlafaxine) on European perch (Perca fluv

40 oprolol, metoprolol, O-desmethylvenlafaxine, tramadol, and venlafaxine.

41 s, capsaicin high-concentration patches, and tramadol; and a weak recommendation for use and proposal

42 Although codeine and tramadol are frequently used in the postoperative period

43 analgesics and anti-inflammatories, such as tramadol, are not preferred in breastfeeding individuals

44 methylamine formation potential (NDMA FP) of tramadol as a model precursor.

45 eparately calculated including and excluding tramadol as an opioid medication.

46 ugs (including acetaminophen, ibuprofen, and tramadol) as an example of increasing analysis throughpu

47 The GC of tramadol at 24 and 48 hr (3.8 +/- 0.4, 5.4 +/- 0.26) wer

48 rong positive correlations with IRSAD, while tramadol, atenolol, and pregabalin had strong negative c

49 We also found fair evidence that opioids, tramadol, benzodiazepines, and gabapentin (for radiculop

50 At equianalgesic doses, tramadol caused less delay in colonic transit than APAP/

51 P450 2D6 (CYP2D6) bioactivates hydrocodone, tramadol, codeine, and oxycodone to active metabolites t

52 oid prescribing that was less pronounced for tramadol compared with typical opioids and was followed

53 rt study, a new prescription dispensation of tramadol, compared with codeine, was significantly assoc

54 Compared with codeine, tramadol dispensation was significantly associated with

55 ne therapy within the clonidine (8 [22.2%]), tramadol ER (7 [19.4%]), or buprenorphine (3 [9.7%]) gro

56 A 7-day taper using clonidine (n = 36), tramadol ER (n = 36), or buprenorphine (n = 31) was then

57 ]; taper mean, 1.54 [SE, .10]; P < .001) and tramadol ER (stabilization mean, 0.53 [SE, .05]; taper m

58 n, 13.1; post-taper mean, 3.2; P < .001) and tramadol ER (taper mean, 7.4; post-taper mean, 2.8; P =

59 Data support further examination of tramadol ER as a method to manage opioid withdrawal symp

60 The results of this trial suggest that tramadol ER is more effective than clonidine and compara

61 ed with clonidine participants (22 [61.1%]); tramadol ER retention was intermediate and did not diffe

62 hmics class III [amiodarone], other opioids [tramadol], glucocorticoids, triazole derivatives, and co

63 uloskeletal injuries with opioids, including tramadol (Grade: conditional recommendation; low-certain

64 nresponders, the mean MEND was 419 mg in the tramadol group and 396 mg in the placebo group (P = 0.70

65 f several drugs on gastrointestinal transit (tramadol HCl, acetaminophen with codeine and placebo) in

66 To evaluate whether tramadol hydrochloride extended-release (ER), an approve

67 metics (low SOE), butorphanol (low SOE), and tramadol in combination with acetaminophen (low SOE) wer

68 electrode was used for the determination of tramadol in infected and healthy human urine and pharmac

69 for 72 h, comparable to the effectiveness of Tramadol in the drinking water.

70 e identified as major reaction mechanisms of tramadol in UV oxidation.

71 prescriptions for hydrocodone decreased and tramadol increased.

72 products (BTPs) of organic micropollutants (tramadol, irgarol, and terbutryn).

73 Tramadol is an alternative to musculoskeletal pain manag

74 Although tramadol is increasingly used to manage chronic noncance

75 Tramadol is one of the most commonly used analgesics wor

76 al anti-inflammatory agents, gabapentinoids, tramadol, lidocaine, and/or the N-methyl-d-aspartate cla

77 ds (such as codeine, dextropropoxyphene, and tramadol) may be effective in the short-term management

78 n to affect pharmacokinetics and efficacy of tramadol, morphine, and codeine.

79 ribed were codeine, oxycodone, propoxyphene, tramadol, morphine, meperidine, fentanyl, or hydroxycodo

80 these pharmacological mechanisms, including tramadol (mu-opioid receptor agonism) and tizanidine (al

81 as significantly lower in patients receiving tramadol (n = 36) than in patients receiving placebo (n

82 Clonidine, meperidine, tramadol, nefopam, and ketamine were the most frequently

83 Among top-ranked repurposed candidate drugs, tramadol, olanzapine, mirtazapine, bupropion, and atomox

84 New prescription dispensation of tramadol or codeine (no dispensation in the previous yea

85 Of the 1 093 064 patients with a tramadol or codeine dispensation during the study period

86 e year of available data and dispensation of tramadol or codeine were included and followed up to Dec

87 inflammatory drugs as first-line therapy, or tramadol or duloxetine as second-line therapy.

88 topical nonsteroidal anti-inflammatory drug, tramadol, or both is recommended.

89 -codamol, paracetamol, codeine, co-dydramol, tramadol, oxycodone, and morphine) during 2005-2010 comp

90 characteristics varied across opioids, with tramadol, oxycodone, methadone, hydromorphone, and morph

91 ; 95% CI, -0.02 to -0.01 pp/quarter), though tramadol prescribing rose by 11.5% overall; and gabapent

92 Tramadol, previously only known as a synthetic analgesic

93 nd to be 0.004 and 0.01 to 20 mumol L(-1) of tramadol, respectively.

94 nts had moderate to very low confidence with tramadol (risk ratio 2.6 (95% confidence interval 1.5 to

95 , 0.46-0.70), with a similar adjusted RR for tramadol (RR, 1.06; 95% CI, 0.73-1.56), and 2- to 3-fold

96 tum, pentazocine, pethidine, tapentadol, and tramadol) to treat chronic nonmalignant pain.

97 The kinetics and oxidation products (OPs) of tramadol (TRA), an opioid, were investigated for its oxi

98 nsteroidal anti-inflammatory drugs (NSAIDs), tramadol, traditional opioids, or adjunctive analgesics.

99 ol studies have shown an association between tramadol use and hypoglycemia.

100 The growing concern over increasing tramadol use and unexpected side effects warranted a fur

101 ers, 6.6% of rosuvastatin users, and 5.8% of tramadol users were reclassified to a lower eGFR for whi

102 and UV/H(2)O(2)/monochloramine oxidation of tramadol using MS(3) capabilities of a hybrid quadrupole

103 hly selective and sensitive determination of tramadol using square wave voltammetry.

104 s a potent alternative to the application of Tramadol via the drinking water.

105 prescribed discharge opioids varied whether tramadol was included (96% each group, P = 1.00) or excl

106 ligram equivalents in the ERAS group whether tramadol was included (median 14.2 vs 57.8, P < 0.001) o

107 7 days) but not immediate pain (<=2 hours), tramadol was ineffective, and opioids increased the risk

108 By 2020, hydrocodone was obtained less and tramadol was obtained more.

109 Tramadol was transformed more and faster than irgarol an

110 Hydrocodone, codeine, oxycodone, and tramadol were the 4 most commonly prescribed opioids.

111 opensity for hypoglycemia in patients taking tramadol when compared to patients taking other opioids,

112 r pain management from first-line opioids to tramadol, which is less safe, and gabapentinoids, which

113 opioid in the last three months (73.33% used tramadol) with 32 non-users.